Repurposing of the childhood vaccines: could we train the immune system against the SARS-CoV-2

被引:7
|
作者
Sharma, Divakar [1 ,2 ]
机构
[1] Hericure Healthcare Pvt Ltd, Pune, Maharashtra, India
[2] Maulana Azad Med Coll, Dept Microbiol, New Delhi 110002, India
关键词
COVID-19; repurposing of vaccines; Bacille Calmette-Guerin (BCG); Measles-Mumps-Rubella (MMR); yellow fever; oral polio vaccine (OPV); BACILLUS-CALMETTE-GUERIN; ORAL POLIO VACCINE; INACTIVATED POLIO; BCG VACCINATION; MORTALITY; MEASLES; PROTECTION; RISK;
D O I
10.1080/14760584.2021.1960161
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction The COVID-19 pandemic is a globalized health concern caused by a beta-coronavirus named Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Since December 2019, when this outbreak flared in Wuhan, China, COVID-19 cases have been continuously rising all over the world. Due to the emergence of SARS-CoV-2 mutants, subsequent waves are flowing in a faster manner as compared to the primary wave, which is more contagious and causing higher mortality. Recently, India has emerged as the new epicenter of the second wave by mutants of SARS-CoV-2. After almost eighteen months of this outbreak, some COVID-19 dedicated therapeutics and vaccines are available, and a few are under trial, but the situation is still uncontrolled. Area covered This perspective article covers the repurposing of childhood vaccines like Bacille Calmette-Guerin (BCG), Measles, Mumps, Rubella (MMR), and Oral Polio Vaccine (OPV), which are live attenuated vaccines and have been shown the protective effect through 'trained immunity and 'crossreactivity.' Expert opinion This perspective article has suggested that combinatorial use of these childhood vaccines might exert a better protective effect along with the available COVID-19 therapeutic and vaccines which could be considered as a preventive option against SARS-CoV-2 infection as well as its subsequent waves.
引用
收藏
页码:1051 / 1057
页数:7
相关论文
共 50 条
  • [1] Immune Response to SARS-CoV-2 Vaccines
    Bellamkonda, Navya
    Lambe, Upendra Pradeep
    Sawant, Sonali
    Nandi, Shyam Sundar
    Chakraborty, Chiranjib
    Shukla, Deepak
    BIOMEDICINES, 2022, 10 (07)
  • [2] Development of vaccines against SARS-CoV-2
    Leon-Lara, Ximena
    Otero-Mendoza, Francisco
    ACTA PEDIATRICA DE MEXICO, 2020, 41 (04): : S23 - S26
  • [3] Immune responses to SARS-CoV-2 vaccines in celiac disease
    Ibsen, Jostein H.
    Chopra, Adity
    Vaage, Eline Benno
    Vaage, John T.
    Lund-Johansen, Fridtjof
    Lundin, Knut E. A.
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2023, 58 (02) : 142 - 147
  • [4] SARS-CoV-2: vaccines in the pandemic era
    Li, Dan-Dan
    Li, Qi-Han
    MILITARY MEDICAL RESEARCH, 2021, 8 (01)
  • [5] SARS-CoV-2 Vaccines: Where Are We Now?
    Flanagan, Katie L.
    MacIntyre, C. Raina
    McIntyre, Peter B.
    Nelson, Michael R.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (10) : 3535 - 3543
  • [6] SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines
    De Leon-Rodriguez, Sarai G.
    Hernandez-Rico, Brenda
    Del Olmo-Vazquez, Guadalupe
    Cruz-Davalos, Ivan
    Bonifaz, Laura C.
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2020, 77 (05): : 252 - 261
  • [7] Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV
    Aherfi, Sarah
    Pradines, Bruno
    Devaux, Christian
    Honore, Stephane
    Colson, Philippe
    La Scola, Bernard
    Raoult, Didier
    FUTURE MICROBIOLOGY, 2021, 16 (17) : 1341 - 1370
  • [8] Original antigenic sin and childhood immune responses against SARS-CoV-2
    Cobey, Sarah
    Hensley, Scott E.
    SCIENCE, 2022, 377 (6611) : 1148 - 1149
  • [9] Nucleic Acid Vaccines against SARS-CoV-2
    Liu, Ying
    Ye, Qing
    VACCINES, 2022, 10 (11)
  • [10] Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2
    Ahluwalia, Pankaj
    Vaibhav, Kumar
    Ahluwalia, Meenakshi
    Mondal, Ashis K.
    Sahajpal, Nikhil
    Rojiani, Amyn M.
    Kolhe, Ravindra
    FRONTIERS IN IMMUNOLOGY, 2021, 12